NCT00377819View on ClinicalTrials.gov

Study of Transitioning From Alendronate to Denosumab

PHASE3CompletedINTERVENTIONAL

Enrollment

504

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

July 31, 2008

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG

alendronate

70 mg oral QW

DRUG

Denosumab (AMG 162)

60 mg SC q 6 mos

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY